Anti-Human LDLR Polyclonal Antibody

Catalog No.

PHB91301

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human LDLR (Gly193-Arg788).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

LDLR, Low-density lipoprotein receptor, LDL receptor

Purification

Purified by antigen affinity column.

Accession

P01130

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

IL-18 inhibition enlarges lesions, necrotic cores and thickens fibrous caps in Jak2 V617F clonal hematopoiesis-driven atherosclerosis., PMID:40501724

cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy., PMID:40444360

Functionalized Boron Carbide Nanoparticles as Active Boron Delivery Agents Dedicated to Boron Neutron Capture Therapy., PMID:40438187

Ertugliflozin attenuates atherosclerosis in nondiabetic ApoE-/- mice by upregulating ABCA1 and LDLR via the PPARγ/LXRα pathway., PMID:40419168

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study., PMID:40181090

Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies., PMID:40110803

Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia., PMID:40022592

Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria., PMID:39964484

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256

In Situ Self-Assembly of Artificial Topological Nanostructures Enhances In Vivo Efficacy of PCSK9 Inhibitory Peptides., PMID:39945488

Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report., PMID:39931866

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy., PMID:39875480

Chitinase-3-like Protein 1 Reduces the Stability of Atherosclerotic Plaque via Impairing Macrophagic Efferocytosis., PMID:39813006

Evaluating the effect of the antiPCSK9 vaccine on systemic inflammation and oxidative stress in an experimental mouse model., PMID:39776050

Homozygous Familial Hypercholesterolemia Treatment: New Developments., PMID:39751968

Low-density Lipoprotein Receptor is an important host factor in flaviviral entry and replication in neurons., PMID:39689643

Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor., PMID:39663455

Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization., PMID:39547850

PCSK9 in metabolism and diseases., PMID:39547595

Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316

Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden mice., PMID:39463193

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors., PMID:39421488

Prevalence of HCV HVR1 insertions and their role in antibody evasion., PMID:39378413

Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis., PMID:39328090

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy., PMID:39163620

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations., PMID:39139638

IL-1β Induces LDL Transcytosis by a Novel Pathway Involving LDLR and Rab27a., PMID:38989581

Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells., PMID:38961200

The Efficacy of Tafolecimab in Chinese Patients with Hypercholesterolemia: A Systematic Review and Meta-analysis., PMID:38913274

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia., PMID:38897173

The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol., PMID:38886277

Evinacumab: Mechanism of action, clinical, and translational science., PMID:38845393

The low-density lipoprotein receptor and apolipoprotein E associated with CCHFV particles mediate CCHFV entry into cells., PMID:38806525

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers., PMID:38796450

A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions., PMID:38755636

Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report., PMID:38695172

PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury., PMID:38657842

PCSK9 inhibitors: a patent review 2018-2023., PMID:38588538

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies., PMID:38545781

Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection., PMID:38528584

Porcine low-density lipoprotein receptor plays an important role in classical swine fever virus infection., PMID:38514916

PCSK9 inhibition protects mice from food allergy., PMID:38471633

Marginal zone B cells produce 'natural' atheroprotective IgM antibodies in a T cell-dependent manner., PMID:38381113

Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis., PMID:38362011

Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics-Pharmacodynamics and Systems Pharmacology., PMID:38357287

LDLR is used as a cell entry receptor by multiple alphaviruses., PMID:38245515

LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus., PMID:38182887

Pseudorabies virus upregulates low-density lipoprotein receptors to facilitate viral entry., PMID:38054618

Identification of benzothiazoles as novel PCSK9 inhibitors., PMID:37939861

Document Download

Anti-Human LDLR Polyclonal Antibody.pdf